Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Oncology Inc. (NasdaqGS: RAIN) is a clinical-stage biotechnology company developing precision therapies targeting specific cancer drivers. This news hub provides investors and researchers with timely updates on the company's progress in oncology innovation, including its lead candidate milademetan and strategic initiatives.
Access authoritative updates on clinical trial developments, regulatory milestones, and corporate announcements. The resource consolidates essential information about RAIN's therapeutic pipeline, financial position, and partnership activities – critical data points for evaluating the company's trajectory in precision medicine.
Key coverage areas include progress in Phase 3 MANTRA trials for liposarcoma, updates on tumor-agnostic basket studies, and analysis of strategic merger plans with Pathos AI. All content maintains rigorous standards for accuracy and clarity, serving both professional investors and those monitoring advancements in cancer treatment.
Bookmark this page for direct access to verified Rain Oncology announcements and objective reporting on developments impacting the company's scientific and financial progress.
Rain Therapeutics reported a net loss of $18.0 million for Q4 2021, leading to a total annual loss of $51.4 million. Despite this, the company maintains a strong cash position of $140.2 million, expected to fund ongoing clinical trials, including a pivotal Phase 3 trial for milademetan in liposarcoma. Both MANTRA and MANTRA-2 trials are progressing on schedule, with all site activations anticipated by Q1 2022. Rain has also entered a supply agreement with Roche for atezolizumab, supporting a Phase 1 combination trial set for later in 2022.
Rain Therapeutics Inc. (NasdaqGS: RAIN) will report its financial results for Q4 and the full year ended December 31, 2021, on March 3, 2022. The late-stage precision oncology firm focuses on developing therapies targeting oncogenic drivers. A conference call will be held on the same day at 1:30 pm PT (4:30 pm ET) to discuss business and financial results. Rain’s lead product, milademetan, is an oral MDM2 inhibitor, and the company is also working on a preclinical program targeting RAD52.
Rain Therapeutics has expanded its leadership team with experienced professionals from notable firms such as Loxo/Lilly, Gilead, Seagen, and AltruBio. Key new appointments include Nora Ku as VP of Clinical Development, Buenaflor Nicolas as VP of Global Drug Safety, Tina Kim-Hafken as VP of Regulatory Affairs, and Steve Flint as VP of People & Culture. Additionally, John Maraganore continues as a Special Advisor since March 2021. These strategic hires aim to enhance Rain’s late-stage clinical and regulatory operations as they develop innovative cancer therapies, particularly the oral inhibitor milademetan.
Rain Therapeutics Inc. (NASDAQ: RAIN) will present a corporate overview at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 pm ET. CEO Avanish Vellanki will lead the presentation, followed by a Q&A session. The presentation will be available for replay on the Rain website for 30 days post-event. Rain specializes in precision oncology, targeting oncogenic drivers and selecting patients based on genetic profiles, with its lead candidate being milademetan, an MDM2 inhibitor effective in various cancers.
Rain Therapeutics Inc. (NASDAQ: RAIN) will participate in two upcoming virtual events. CEO Avanish Vellanki will present at the B. Riley Securities Oncology Investor Conference on January 27, 2022, at 3:30 pm ET. Additionally, Rain will be featured in a virtual fireside chat at the Guggenheim Oncology Conference on February 10, 2022, at 4:00 pm ET. Both events will provide insights into the company's precision oncology therapies, including their leading candidate, milademetan. Replays of these presentations will be available on Rain’s official website for 30 days post-event.
Rain Therapeutics Inc. has announced a clinical supply agreement with Roche to evaluate the combination of milademetan, an MDM2 inhibitor, with atezolizumab, a PD-L1 antibody, targeting genetically selected cancer patients. This agreement includes plans for a Phase 1 trial assessing safety and efficacy in patients with specific tumors, with a launch expected in the second half of 2022. Rain is also advancing milademetan's use in other ongoing trials for various cancers and has received FDA Orphan Drug Designation for liposarcoma.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at two upcoming virtual conferences: the JP Morgan Chase 40th Annual Healthcare Conference on January 13, 2022, and the H.C. Wainwright Bioconnect Conference starting January 10, 2022. The JP Morgan presentation will be live at 11:15 a.m. ET, while H.C. Wainwright will feature a prerecorded session available from 7:00 a.m. ET. Both events highlight Rain's focus on precision oncology, targeting therapies for genetically selected patients.
Rain Therapeutics Inc. (NASDAQ: RAIN) announced its inclusion in the NASDAQ Biotechnology Index (NBI), effective December 20, 2021. This index tracks NASDAQ-listed companies in the biotechnology and pharmaceuticals sector. To qualify, companies must have a market cap of at least $200 million and an average daily trading volume of 100,000 shares. Rain Therapeutics focuses on developing precision oncology therapies, including its lead candidate, milademetan, an oral MDM2 inhibitor targeting various cancers. This index inclusion may enhance visibility and investment interest in Rain.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that its CEO, Avanish Vellanki, will partake in two upcoming virtual conferences: the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021, and the Evercore ISI 4th Annual Health CONx Virtual Conference on December 2, 2021. The Piper Sandler presentation will be available starting November 22, 2021, at 10:00 a.m. ET. Both events will include webcasts accessible through Rain's website, with replays available for 30 days post-presentation. Rain focuses on precision oncology, developing targeted therapies for cancer.
Rain Therapeutics has initiated the Phase 2 MANTRA-2 trial to assess the safety and efficacy of milademetan, an MDM2 inhibitor, in patients with MDM2-amplified advanced solid tumors. The trial aims to enroll approximately 65 patients refractory to standard therapies, focusing on wild-type p53 tumors. The primary endpoint is the objective response rate. Interim results are expected in late 2022. Milademetan has shown promise in earlier trials, including a Phase 1 study demonstrating anti-tumor activity in liposarcoma and other solid tumors.
FAQ
What is the current stock price of Rain Enhancement (RAIN)?
What is the market cap of Rain Enhancement (RAIN)?
